Home News

ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies

Thu, 21/12/2017 - 18:33 0 min
No votes yet
 
Related
Financial Results Nine month period 2019 - Video
0 min
25/11/2019
ROVI reports operating revenue growth of 24% and EBITDA growth of 83%
Operating revenue increased by 24% to 270.8 million euros in the first nine months of 2019, mainly driven by the strength of the...
5 min
07/11/2019
ROVI announces the construction of a second heparin plant in Granada
Laboratorios Farmacéuticos Rovi, S.A. (“ROVI”) has announced the future construction of a new manufacturing plant for the active substance...
3 min
05/09/2019